Pra Health (PRAH) Fundamental Analysis & Valuation

NASDAQ:PRAH

Current stock price

165.21
-2.8 (-1.67%)
At close:
166.01
+0.8 (+0.48%)
After Hours:

This PRAH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PRAH Profitability Analysis

1.1 Basic Checks

  • PRAH had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 4.98%
ROE 13.71%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 10.03%
PM (TTM) 6.4%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. PRAH Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for PRAH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

  • PRAH has an Altman-Z score of 3.56. This indicates that PRAH is financially healthy and has little risk of bankruptcy at the moment.
  • PRAH has a Debt/Equity ratio of 0.74. This is a neutral value indicating PRAH is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z 3.56
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

  • PRAH has a Current Ratio of 1.21. This is a normal value and indicates that PRAH is financially healthy and should not expect problems in meeting its short term obligations.
  • PRAH has a Quick Ratio of 1.21. This is a normal value and indicates that PRAH is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. PRAH Growth Analysis

3.1 Past

  • PRAH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.36%.
  • The Earnings Per Share has been growing by 19.06% on average over the past years. This is quite good.
  • PRAH shows a small growth in Revenue. In the last year, the Revenue has grown by 6.57%.
  • Measured over the past years, PRAH shows a quite strong growth in Revenue. The Revenue has been growing by 14.55% on average per year.
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS Q2Q%28.57%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Sales Q2Q%19.15%

3.2 Future

  • Based on estimates for the next years, PRAH will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.49% on average per year.
  • The Revenue is expected to grow by 9.45% on average over the next years. This is quite good.
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PRAH Yearly Revenue VS EstimatesPRAH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B
PRAH Yearly EPS VS EstimatesPRAH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

1

4. PRAH Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 32.65, PRAH can be considered very expensive at the moment.
  • PRAH is valuated rather expensively when we compare the Price/Earnings ratio to 25.54, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 23.77, PRAH is valued on the expensive side.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, PRAH is valued at the same level.
Industry RankSector Rank
PE 32.65
Fwd PE 23.77
PRAH Price Earnings VS Forward Price EarningsPRAH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.96
PRAH Per share dataPRAH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as PRAH's earnings are expected to grow with 16.62% in the coming years.
PEG (NY)1.12
PEG (5Y)1.71
EPS Next 2Y20.83%
EPS Next 3Y16.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRAH Dividend Analysis

5.1 Amount

  • No dividends for PRAH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

PRAH Fundamentals: All Metrics, Ratios and Statistics

Pra Health

NASDAQ:PRAH (6/30/2021, 8:12:54 PM)

After market: 166.01 +0.8 (+0.48%)

165.21

-2.8 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A
Earnings (Next)03-01
Inst Owners0%
Inst Owner Change-99.98%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap10.70B
Revenue(TTM)3.33B
Net Income(TTM)213.32M
Analysts60
Price Target171.11 (3.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 32.65
Fwd PE 23.77
P/S 3.21
P/FCF N/A
P/OCF N/A
P/B 6.88
P/tB N/A
EV/EBITDA 23.96
EPS(TTM)5.06
EY3.06%
EPS(NY)6.95
Fwd EY4.21%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS51.45
BVpS24.02
TBVpSN/A
PEG (NY)1.12
PEG (5Y)1.71
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 4.98%
ROE 13.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 10.03%
PM (TTM) 6.4%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z 3.56
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS Q2Q%28.57%
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Sales Q2Q%19.15%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Pra Health / PRAH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Pra Health?

ChartMill assigns a fundamental rating of 3 / 10 to PRAH.


What is the valuation status for PRAH stock?

ChartMill assigns a valuation rating of 4 / 10 to Pra Health (PRAH). This can be considered as Fairly Valued.


Can you provide the profitability details for Pra Health?

Pra Health (PRAH) has a profitability rating of 4 / 10.


Can you provide the financial health for PRAH stock?

The financial health rating of Pra Health (PRAH) is 3 / 10.


What is the earnings growth outlook for Pra Health?

The Earnings per Share (EPS) of Pra Health (PRAH) is expected to grow by 29.21% in the next year.